| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Desisobutyryl-ciclesonide targets the glucocorticoid receptor (GR). As a glucocorticoid receptor agonist, it binds to the GR with high affinity and activates it. This leads to the modulation of gene expression, resulting in potent anti-inflammatory effects. It is a potent and specific beta-adrenergic agonist.
|
|---|---|
| ln Vitro |
Ciclesonide is an inhaled corticosteroid with limited affinity for the glucocorticoid receptor and, when converted to the active metabolite isobutyrylciclesonide, is particularly effective in downregulating the pro-inflammatory activity of airway parenchymal cells in vitro . 0.3-3.0 μM ciclesonide and desisobutyryl-ciclesonide can dose-dependently reduce the proliferation of peripheral blood mononuclear cells against Candida albicans, but the inhibitory action of desisobutyryl-ciclesonide is more strong. high. Significant proliferation of PhlP5 was only observed in cultures from atopic subjects: effective downregulation was detected at 0.03 μM ciclesonide and 0.003 μM deisobutyrylciclesonide (at 3 μM ciclesonide De and 0.03 μM deisobutyryl ciclesonide fully stopped). 3 μM Ciclesonide and Desisobutyryl-ciclesonide inhibited PhlP5-specific T cell blast growth and the fraction of interleukin-4-producing cells. In PBMC cultures from atopic patients, both ciclesonide (CIC) and desisobutyrylciclesonide (des-CIC) elicited a dose-dependent downregulation of PhlP5-driven proliferation. The effect of 0.03 μM ciclesonide and 0.003 μM desisobutyrylciclesonide was already substantial (p<0.001 for each comparison) and was observed at 3 μM ciclesonide and 0.03 μM desisobutyrylciclesonide Completely inhibited at early stage. The inhibitory action of Desisobutyryl-ciclesonide at 0.003 μM (p<0.05), 0.03 μM (p<0.001) and 0.3 μM (p<0.05) on PhlP5-induced PBMC proliferation was stronger than that of Ciclesonide [1].
In vitro, Desisobutyryl-ciclesonide exhibits potent anti-inflammatory activity. It has high affinity for the glucocorticoid receptor. Its activity is typically measured by its ability to inhibit the production of inflammatory cytokines from immune cells, such as TNF-α and IL-6, in response to a stimulus like LPS. |
| ln Vivo |
In vivo, Desisobutyryl-ciclesonide is the active metabolite responsible for the therapeutic effects of ciclesonide. It is produced locally in the lungs after inhalation of the prodrug. It exerts potent anti-inflammatory effects, reducing airway inflammation and hyperresponsiveness in asthma. Its local activation minimizes systemic side effects.
|
| Enzyme Assay |
In vitro receptor binding assays are performed to measure the affinity of Desisobutyryl-ciclesonide for the glucocorticoid receptor. The compound is incubated with a radiolabeled glucocorticoid and the receptor. The displacement of the radioligand is measured, and the binding affinity (Ki) is calculated.
|
| Cell Assay |
Cellular assays are performed using immune cells like macrophages or lymphocytes. Cells are treated with Desisobutyryl-ciclesonide and then stimulated with an inflammatory agent. The production of inflammatory cytokines is measured by ELISA or qPCR. The compound's ability to inhibit the inflammatory response is quantified.
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of asthma. Animals are sensitized and challenged with an allergen. Desisobutyryl-ciclesonide is administered via inhalation. Airway inflammation is assessed by analyzing bronchoalveolar lavage fluid for inflammatory cells and cytokines. Airway hyperresponsiveness is measured by methacholine challenge.
|
| ADME/Pharmacokinetics |
Desisobutyryl-ciclesonide has a molecular weight of 470.60 g/mol and a chemical formula of C28H38O6. It is the active metabolite formed from the prodrug ciclesonide. Its local formation in the lungs ensures high target-site concentrations while minimizing systemic exposure and associated side effects.
|
| Toxicity/Toxicokinetics |
Desisobutyryl-ciclesonide is generally well-tolerated as it is the active metabolite of a widely used inhaled corticosteroid. The prodrug design minimizes systemic bioavailability, which reduces the risk of systemic side effects associated with corticosteroids.
|
| References | |
| Additional Infomation |
Desisobutyryl-ciclesonide is the active principle of ciclesonide, a novel corticosteroid for the treatment of asthma. It is formed locally in the lung, thereby minimizing systemic effects on endogenous cortisol. It is a potent glucocorticoid receptor agonist.
|
| Molecular Formula |
C₂₈H₃₈O₆
|
|---|---|
| Molecular Weight |
470.60
|
| Exact Mass |
470.267
|
| CAS # |
161115-59-9
|
| Related CAS # |
Ciclesonide;126544-47-6
|
| PubChem CID |
6918281
|
| Appearance |
White to off-white solid powder
|
| Density |
1.284g/cm3
|
| Boiling Point |
640.778ºC at 760 mmHg
|
| Melting Point |
129-132ºC
|
| Flash Point |
211.522ºC
|
| LogP |
3.497
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
34
|
| Complexity |
949
|
| Defined Atom Stereocenter Count |
9
|
| SMILES |
C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1C[C@@H]4[C@]2(O[C@@H](O4)C5CCCCC5)C(=O)CO)CCC6=CC(=O)C=C[C@]36C)O
|
| InChi Key |
OXPLANUPKBHPMS-ZXBNPROVSA-N
|
| InChi Code |
InChI=1S/C28H38O6/c1-26-11-10-18(30)12-17(26)8-9-19-20-13-23-28(22(32)15-29,27(20,2)14-21(31)24(19)26)34-25(33-23)16-6-4-3-5-7-16/h10-12,16,19-21,23-25,29,31H,3-9,13-15H2,1-2H3/t19-,20-,21-,23+,24+,25+,26-,27-,28+/m0/s1
|
| Chemical Name |
(1S,2S,4R,6R,8S,9S,11S,12S,13R)-6-cyclohexyl-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one
|
| Synonyms |
CIC-AP Ciclesonide active principle
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~212.49 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.31 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.31 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1249 mL | 10.6247 mL | 21.2495 mL | |
| 5 mM | 0.4250 mL | 2.1249 mL | 4.2499 mL | |
| 10 mM | 0.2125 mL | 1.0625 mL | 2.1249 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
